These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16690468)

  • 41. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia.
    Brümmer D; Evans D; Berg D; Greten H; Beisiegel U; Mann WA
    J Mol Med (Berl); 1998 Apr; 76(5):355-64. PubMed ID: 9587070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency.
    Mabuchi H; Itoh H; Takeda M; Kajinami K; Wakasugi T; Koizumi J; Takeda R; Asagami C
    Metabolism; 1989 Feb; 38(2):115-9. PubMed ID: 2492364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.
    Mahley RW; Huang Y; Rall SC
    J Lipid Res; 1999 Nov; 40(11):1933-49. PubMed ID: 10552997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Orange skin and xanthomas associated with lycopenaemia in a setting of type III dyslipoproteinemia].
    Royer M; Bulai Livideanu C; Periquet B; Maybon P; Lamant L; Mazereeuw-Hautier J; Ferrières J; Paul C
    Ann Dermatol Venereol; 2009 Jan; 136(1):42-5. PubMed ID: 19171229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
    Feussner G; Eichinger M; Ziegler R
    Clin Investig; 1992 Nov; 70(11):1027-35. PubMed ID: 1472833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resequencing the APOE gene reveals that rare mutations are not significant contributory factors in the development of type III hyperlipidemia.
    Evans D; Beil FU; Aberle J
    J Clin Lipidol; 2013; 7(6):671-4. PubMed ID: 24314366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
    de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
    J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.
    Sullivan PM; Mezdour H; Quarfordt SH; Maeda N
    J Clin Invest; 1998 Jul; 102(1):130-5. PubMed ID: 9649566
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response to therapy of a type III hyperlipoproteinemic subject with the rare apolipoprotein E1 (Gly127----Asp, Arg158----Cys) variant.
    Feussner G; Ziegler R
    Clin Investig; 1992 Jul; 70(7):614-7. PubMed ID: 1392432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
    Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
    Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia.
    Feussner G; Dobmeyer J; Gröne HJ; Lohmer S; Wohlfeil S
    Am J Hum Genet; 1996 Feb; 58(2):281-91. PubMed ID: 8571954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Apolipoprotein E deficiency associated with type III hyperlipoproteinemia--analysis of apolipoprotein E].
    Tsukamoto H; Hirose H; Dan K; Ishii K; Kikuchi H; Murata M
    Rinsho Byori; 2006 Feb; 54(2):121-5. PubMed ID: 16548231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
    Matsunaga A; Saito T
    Clin Exp Nephrol; 2014 Apr; 18(2):220-4. PubMed ID: 24570178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The spectrum of type III hyperlipoproteinemia.
    Sniderman AD; de Graaf J; Thanassoulis G; Tremblay AJ; Martin SS; Couture P
    J Clin Lipidol; 2018; 12(6):1383-1389. PubMed ID: 30318453
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan.
    Kobori S; Nakamura N; Uzawa H; Shichiri M
    Atherosclerosis; 1988 Jan; 69(1):81-8. PubMed ID: 3355609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Relationship between gene polymorphism at the apolipoprotein E locus and serum lipid profile in urban children of school age in Beijing].
    Zhu W; Feng N; Wang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Sep; 35(5):297-300. PubMed ID: 11769625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Compound heterozygote for both rare apolipoprotein E1 (Gly127-->Asp, Arg158-->Cys) and E3(Cys112-->Arg, Arg251-->Gly) alleles in a multigeneration pedigree with hyperlipoproteinaemia.
    Richard P; Beucler I; Pascual De Zulueta M; Biteau N; De Gennes JL; Iron A
    Clin Sci (Lond); 1997 Jul; 93(1):89-95. PubMed ID: 9279208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.
    Wang R; Zhao C; Chen W; Liu Z; Xie F
    J Med Case Rep; 2022 Feb; 16(1):78. PubMed ID: 35193676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diabetic lipemia with eruptive xanthomatosis in a lean young female with apolipoprotein E4/4.
    Shinozaki S; Itabashi N; Rokkaku K; Ichiki K; Nagasaka S; Okada K; Fujimoto M; Ohtsuki M; Ishibashi S
    Diabetes Res Clin Pract; 2005 Nov; 70(2):183-92. PubMed ID: 16188578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.